Drug maker's latest ranking sits as Roche replaces Pfizer

Pharmaceutical Network July 6th, pharmaceutical companies ranking shuffle came
1, pharmaceutical companies ranking shuffling, Roche replaced Pfizerrecently, the United States "Pharmaceutical Managers" published the 2020 global pharmaceutical companies list of the top 50, and attached to the list of pharmaceuticalcompaniesthe annual sales ranking of prescription drugsAccording to the latest full-year drug revenue statistics, the financial impact of the new coronapneumonia is small for the top 50 drug companiesThe top 10, however, experienced its biggest change in years, partly as a result of large mergers,Roche's sales rose 8.3 per cent, up one place, ending Pfizer's four-year dominance in the rankingsAvastin (Bevalzumab) remains Roche's best-selling product, accounting for 15% of the company's totaldrugrevenueBut in the next few years, the three carriages will face competition from biosimilars, as will the quordal and rituximabAs the business grew, Roche's main sales drivers came from the multi-hardening drug Ocrevus, the hemophilia drug Hemlibra, and Tecentriq and Perjeta cancer treatmentsIn a rare way, Roche is the only drug maker to have topped the list in recent years for both drug revenues and research and development spending: Roche Pharmaceuticals has grossed $10.3 billion, and the only drug company to invest more than $1 billion in research and development2
, affected by large-scale acquisitions of pharmaceutical companies
in addition to Roche, Novartis also rose one place from the previous ranking, jumping from third to second place, drug sales rose 6% 　　In January, the big pharmaceutical company completed its $9.7 billion acquisition of The Medicines Company and acquired inclisiran, a potentially best-in-class cholesterol-lowering treatment that works by using the natural mechanisms of human RNA silencing Novartis' heart failure drug Entresto grew 74 percent in the fourth quarter of 2019 to $1.7 billion for the full year; 　　The remaining three companies in the top five are Pfizer, Mercado and Baxter Pfizer fell two places and prescription drug sales fell 3.6 percent, in part because of a drop in fourth-quarter sales of its nerve pain drug Lyrica, a multi-competitive generic drug Sales of the breast cancer treatment drug Ibrance rose 20.5 percent last year 　　Pfizer completed its $11.4 billion acquisition of cancer-focused BioPharma bioPharma in July 2019 and expects future sales of other brands such as Eliquis, Xeljanz, Xtandi and Inlyta to continue to grow 　　Mercado's sales revenue is still strongly affected by K-drugs, with its cancer immunotherapy Keytruda sales up 9.5 percent to $11.1 billion, up 54.5 percent, as the drug continues to receive approval for new indications 　　Taken together, the reshuffle of this ranking has a direct impact on the recent large-scale mergers and acquisitions 　　BMS rose from 11th to 5th as The Pharmaceutical Manager included prescription drug sales at new-based pharmaceuticals Last year, BMS officially bought New Base Pharmaceuticals for $74 billion, and New Base Pharmaceuticals' Revlimid generated nearly $11 billion in sales, followed by BMS's Eliquis, up 23 percent year-on-year 　　In addition, THE DEMAND FOR BLOOD THINNERS FOR THE COVID-19, A PARTNERSHIP BETWEEN BMS AND PFIZER, INCREASED ITS REVENUE BY 37 PERCENT TO $2.6 BILLION IN THE FIRST QUARTER OF 2020 　　In the research and development cost index, BMS and New Base Pharmaceuticals spent $9.4 billion last year, second only to Roche, Johnson and Johnson and Mercatom in third and fourth place, respectively It's worth noting that in early 2020, brand finance, an independent brand business evaluation firm, named Johnson and Johnson the most valuable pharmaceutical company in 2020 due to its strong research and development capabilities, particularly in antimicrobials, and was one of the first companies to announce the development of vaccines during the outbreak of new crown pneumonia 　　In line with BMS, Takeda Pharmaceuticals' ranking jumped significantly because of a major pharmaceutical acquisition Takeda Pharmaceuticals also made it into the top 10 of the world's top 50 pharmaceutical companies because of its acquisition of Shire, with the Japanese drugmaker's revenue growing 67.8 percent in its first year of acquisitions 　　Although AbbVie (ranked 8) finally completed its $62 billion acquisition of Aljian (rank18) last month, the two have yet to be combined, largely because the popularity of the new crown has delayed progress on the important merger So in the next 1-2 years, AbbVie's global ranking could quickly rise to the top five 　　3, four Chinese pharmaceutical companies on the list, Yunnan white medicine rose the fastest
in addition, China's four pharmaceutical companies Yunnan White Pharmaceuticals (ranked 37), China Biopharmaceuticals (ranked 42), Jiangsu Hengrui Pharmaceutical (43), Shanghai Pharmaceutical Group (48) on the list 　　Compared with last year's TOP50 global rankings, Yunnan white medicine rose the fastest, last year not in the list, this year has jumped to 37, China's biopharmaceutical ranking unchanged, Hengrui Pharmaceutical sipulsible ranking rose 4 places, Shanghai Pharmaceutical Group's latest list 　　Yunnan White Medicine's 2019 annual report shows that in 2019, operating income and home-to-home net profit were about 29.66 billion yuan and 4.18 billion yuan, respectively, with yoY growth rates of about 9.8% and 19.8%, respectively, while net profit was 2.29 billion yuan, down 22.9% YoY 2019Q4 operating income and net profit attributed to the parent son were about 8 billion yuan and 640 million yuan, respectively, with yoY growth rates of about 13.9% and 225%, respectively 　　By sector, the pharmaceutical industry and commerce were about 11.02 billion yuan and 18.55 billion yuan, respectively, with year-on-year growth rates of about 1.9% and 16.5%, respectively According to the sub-sector, the provincial pharmaceutical company is about 19 billion yuan (16.4%), the pharmaceutical division is about 4.4 billion yuan (-3%), the Health Division is about 4.68 billion yuan (plus 4.8%), and the Chinese medicine resources division is about 1.37 billion yuan (flat), which is in line with expectations 　　As a large pharmaceutical company with a large body, Yunnan White Medicine is still growing at a relatively fast rate, which is one of the reasons why it entered the TOP50 global pharmaceutical rankings this year without being listed last year 　　Although China's biopharmaceutical ranking remained unchanged, Hengrui Pharmaceuticals rose 4 places to 43, with its 2019 annual report showing revenue of 23.289 billion yuan, up 33.70 percent yoy, and net profit attributed to parents was 5.328 billion yuan, up 31.05 percent year-on-year 　　In the rankings, Henri Pharma's apatimini, heptafluorane and right-hand metormia were among its best-selling drugs, with sales of $336 million, $287 million and $233 million, respectively 　　As far as the final sales of the best-selling drugs are concerned, the sales of Chinese pharmaceutical companies are still far from the top 10, according to medical geographic statistics, the sales revenue of the top 10 pharmaceutical companies in the first 10 accounted for 54.1% of the total sales revenue before the top 50, and the sales revenue of the top 20 companies accounted for 78.9%